Replies to post #217947 on Biotech Values

[DewDiligence]

Mavyret’s US market share—week ending 3/16/18 (according to IMS):

• ABBV/ENTA’s NRx share=42.9%, down marginally from the highest-ever 43.1% in the preceding week.

• ABBV/ENTA’s TRx share=36.6%, down slightly from the highest-ever 38.2% in the preceding week.

Has mavyret's US market share topped out? Unlikely, IMO.

(Almost all of ABBV/ENTA’s US HCV business now comes from Mavyret.)